Four-factor prothrombin complex concentrate versus plasma for urgent vitamin K antagonist reversal: new evidence

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Vitamin K antagonist (VKA) therapy is a mainstay of treatment for patients at risk of thromboembolic events. Despite widespread use, a major limitation of VKA therapy is the substantial risk of serious bleeding complications, which often require rapid reversal of anticoagulation. A recent randomized multicenter comparison between a 4-factor prothrombin complex concentrate (4F-PCC) and plasma in patients with acute major bleeding has provided important new evidence of the benefit of 4F-PCC over plasma for urgent VKA reversal.

Original languageEnglish (US)
Pages (from-to)613-621
Number of pages9
JournalClinics in Laboratory Medicine
Volume34
Issue number3
DOIs
StatePublished - Sep 1 2014

Keywords

  • Anticoagulants
  • Hemorrhage
  • Plasma
  • Prothrombin complex concentrates
  • Vitamin K antagonist

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Four-factor prothrombin complex concentrate versus plasma for urgent vitamin K antagonist reversal: new evidence'. Together they form a unique fingerprint.

Cite this